This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: L40.00 | Special Copayment Reduction: V280 (severe intractable disease, 5 years) |
| B. Synonyms | severe plaque psoriasis, severe psoriasis vulgaris |
| C. Adult onset | Adult onset very high — the age of onset of psoriasis is bimodal (20s–30s, 50s–60s), and severe psoriasis vulgaris mainly presents in adults. Childhood onset accounts for about 30% of the total, but severe adult psoriasis carries a greater treatment burden. |
| 1. History | See main text |
| 2. Causes | See main text |
| 3. Genetics | See main text |
| 4. General epidemiology | See main text |
| 5. Pathophysiology | See main text |
| 6. Symptoms | See main text |
| 7. Signs | See main text |
| 8. Screening | See main text |
| 9. Diagnosis | See main text |
| 10. Treatment | See main text |
| 11. Prognosis | See main text |
| 12. Prevention | See main text |
| 13. References | See main text |
Psoriasis is a skin disease known since several thousand years BC, recorded in ancient Egyptian papyri and Hippocratic texts as a 'dry, scaly skin disease'. However, confusion with leprosy persisted for a long time. In 1801, the English physician Robert Willan first clearly distinguished psoriasis from leprosy and named it 'Psoriasis', and in 1841 Heinrich Köbner described the phenomenon of psoriasis developing at sites of skin trauma (Köbner phenomenon).
Until the early 20th century, treatment of psoriasis relied on topical preparations such as tar, salicylic acid, and anthralin (dithranol). In 1923, Goeckerman developed a treatment combining ultraviolet light and tar, and systemic ultraviolet therapy was introduced after 1953. In 1958, PUVA (psoralen + UVA) treatment was developed and used for severe psoriasis. Methotrexate in the 1970s, retinoids (acitretin) in the 1980s, and cyclosporine in the 1990s were introduced as systemic treatments for severe psoriasis.
The introduction of biologics after the 2000s changed the paradigm of severe psoriasis treatment. Beginning with etanercept (anti-TNF) in 2003, adalimumab (2008), infliximab (2006), ustekinumab (anti-IL-12/23, 2009), secukinumab (anti-IL-17A, 2015), ixekizumab (anti-IL-17A, 2016), bimekizumab (anti-IL-17A/F, 2021), guselkumab (anti-IL-23p19, 2017), risankizumab (anti-IL-23p19, 2019), tildrakizumab (2018), and others were approved, so that treatment results close to complete skin clearance can now be achieved in severe psoriasis.
The cause of severe psoriasis vulgaris is understood as a complex interaction of genetic predisposition and environmental factors.
The HLA-Cw*06:02 allele (PSORS1 locus) is the strongest genetic risk factor for psoriasis, especially early-onset psoriasis (type I, before age 40). HLA-Cw6 carriers have an approximately 5–20-fold increased risk of psoriasis. In addition, more than 80 susceptibility loci have been identified, including IL-23R, IL-12B, TNF-α, the LCE (late cornified envelope) gene cluster, TYK2, and TRAF3IP2 (ACT1).
T cells responding to autoantigens (keratinocyte-derived LL-37, ADAMTSL5, etc.) are activated and secrete IL-17A, IL-17F, IL-22, TNF-α, and IFN-γ, and these cytokines cause hyperproliferation and abnormal differentiation of keratinocytes. IL-23 is the key upstream cytokine promoting the maintenance and activation of Th17 cells and tissue-resident memory T cells (T_RM).
Streptococcus (Group A Streptococcus) associated with tonsillitis and pharyngitis can trigger guttate psoriasis. Beta-blockers, lithium, antimalarials, abrupt steroid tapering, and NSAIDs worsen psoriasis. Smoking, excessive alcohol consumption, obesity, stress, and skin trauma (Köbner phenomenon) are major exacerbating factors.
The genetic basis of psoriasis has been extensively explored through twin studies, family studies, and GWAS. The concordance rate in monozygotic twins is about 35–70%, suggesting the importance of genetic factors. More than 80 psoriasis susceptibility loci have currently been identified.
PSORS1 locus (6p21.3): The PSORS1 locus, which includes HLA-Cw*06:02 (or Cw6), is the strongest locus, explaining about 35–50% of the genetic risk of psoriasis. In Cw6-positive psoriasis patients, it is associated with specific clinical phenotypes such as guttate psoriasis onset after streptococcal infection, early-onset type (type I), and scalp psoriasis.
IL-23/IL-17 pathway genes: The R381Q variant of the IL-23R gene reduces psoriasis risk, confirming that the IL-23 signaling pathway is central to the pathophysiology of psoriasis. IL-12B (p40 subunit), TYK2, TRAF3IP2 (ACT1, IL-17 signaling adaptor), NFKBIA, TNFAIP3 (A20), and others determine psoriasis susceptibility in the IL-17 and TNF signaling pathways.
Keratinocyte-related genes: Deletion variants of the LCE3B and LCE3C genes in the LCE (late cornified envelope) gene cluster (1q21) are associated with psoriasis susceptibility. These genes are involved in skin barrier function and the keratinization process. Copy number variation of the DEFB4 (β-defensin 4) gene is also associated with psoriasis risk.
Psoriasis is one of the most common chronic immune-mediated skin diseases, with a worldwide prevalence of about 2–3%. The prevalence in Korea is about 0.5–1%, lower than in the West, but is increasing with urbanization and Westernization. Severe psoriasis vulgaris (BSA >10% or PASI >10) accounts for about 20–30% of all psoriasis.
The age of onset of psoriasis shows a bimodal distribution. Type I (early onset, before age 40, about 75%) has a high proportion of HLA-Cw6 positivity, a common family history, and more extensive lesions. Type II (late onset, after age 40) is more often HLA-Cw6 negative and has a higher frequency of accompanying arthritis. The male-to-female ratio is almost equal. The proportion of psoriasis patients with psoriatic arthritis (PsA) is about 20–30%, and higher in severe psoriasis. Cardiovascular disease (myocardial infarction, stroke), metabolic syndrome, type 2 diabetes, obesity, depression/anxiety, and inflammatory bowel disease (especially Crohn disease) are increased as comorbidities, reflecting the systemic inflammatory burden of psoriasis.
The pathophysiology of severe psoriasis vulgaris is explained as a vicious cycle of T cell-mediated autoimmune response and keratinocyte hyperproliferation.
Stimuli such as skin trauma, infection (streptococcus), and stress cause keratinocytes to secrete TSLP, IL-33, and IL-1α, and dendritic cells (plasmacytoid dendritic cells, pDC) recognize complexes of the antimicrobial peptide (LL-37) and self DNA and produce IFN-α and IFN-β. These type I interferons promote dendritic cell maturation and production of IL-23 and IL-12.
IL-23 secreted by skin dendritic cells drives differentiation of CD4+ T cells into Th17 cells. IL-17A, IL-17F, IL-22, and TNF-α are secreted from Th17 cells and tissue-resident memory T cells (CD8+ T_RM). IL-23 is the key cytokine maintaining the presence and activation of Th17 cells and is the main target of anti-IL-23 biologics.
IL-17A and TNF-α induce keratinocytes to secrete additional inflammatory cytokines (IL-6, IL-8, CXCL1, CXCL5) and promote infiltration of neutrophils and T cells into the skin. IL-22 directly stimulates keratinocyte hyperproliferation and inhibits differentiation, causing hyperkeratosis and silvery-white scale formation. The epidermal turnover cycle is markedly shortened (3–5 days) in psoriasis compared with normal (28–30 days).
The clinical symptoms of severe psoriasis vulgaris are characterized by extensive skin lesions, pruritus, pain, and systemic and joint symptoms.
The typical finding is a well-demarcated erythematous plaque covered with silvery-white scale. In severe psoriasis vulgaris, PASI (Psoriasis Area and Severity Index) ≥10 or BSA (body surface area) >10%, with extensive involvement of the body surface. Lesions preferentially occur at sites subject to pressure and trauma, such as the scalp, behind the ears, elbows, knees, sacral area, and around the umbilicus. Intense pruritus, skin pain, and dryness accompany. Auspitz sign: pinpoint bleeding appears when the scale is removed.
Nail involvement occurs in about 50% of psoriasis patients and is more frequent in severe psoriasis. Nail pitting, onycholysis, subungual hyperkeratosis, and the oil drop sign are characteristic. Nail psoriasis shows a strong association with psoriatic arthritis.
Patients with severe psoriasis may have various systemic complications, including psoriatic arthritis (arthralgia, swelling, stiffness), increased cardiovascular risk (myocardial infarction, stroke), metabolic syndrome (obesity, hyperlipidemia, hypertension, diabetes), inflammatory bowel disease (Crohn disease), uveitis, and depression/anxiety.
On physical examination, well-demarcated erythematous plaques and silvery-white scale are observed. The Auspitz sign and Köbner phenomenon are characteristic. PASI, BSA, DLQI (Dermatology Life Quality Index), and IGA (Investigator Global Assessment) scores are used to assess severity. Severe: PASI ≥10, BSA >10%, DLQI >10. For evaluation of psoriatic arthritis, joint examination (tender/swollen joint count, Leeds Enthesitis Index, SPARCC score) is performed.
Laboratory findings may show elevated inflammatory markers (CRP, ESR), increased uric acid (when psoriasis and gout coexist), and abnormal metabolic indicators (fasting glucose, lipid profile). Radiography can show characteristic findings of psoriatic arthritis (soft tissue swelling, erosions, 'pencil-in-cup' deformity, spinal proliferation, etc.). HLA-Cw6 genotyping is used in research contexts but is not recommended as a general clinical screening test.
Psoriasis screening of the general population is not recommended. However, in patients with severe psoriasis, regular screening for comorbidities such as cardiovascular risk factors (hypertension, diabetes, hyperlipidemia, obesity), psoriatic arthritis, depression/anxiety, and inflammatory bowel disease is important.
Psoriatic arthritis screening: In psoriasis patients with arthralgia, joint swelling, or nail psoriasis, psoriatic arthritis is actively evaluated. The PEST (Psoriasis Epidemiology Screening Tool) or ToPAS (Toronto Psoriatic Arthritis Screen) questionnaire is used for psoriatic arthritis screening.
Cardiovascular screening: Severe psoriasis is an independent risk factor for cardiovascular disease, so regular measurement of blood pressure, blood glucose, lipids, and weight is needed. It is recommended that psoriasis-related risk be additionally reflected in 10-year cardiovascular risk calculation (Framingham risk score, SCORE).
Diagnosis of severe psoriasis vulgaris is mainly based on clinical findings. Clinical diagnosis is possible when typical lesions (well-demarcated erythematous plaques, silvery-white scale) are distributed at characteristic sites. When confirmation or differential diagnosis is difficult, a skin biopsy is performed. Histopathology is characterized by irregular epidermal hyperplasia (psoriasiform hyperplasia), alternating parakeratosis, acanthosis, collections of neutrophils within the epidermis (Munro's microabscess), vascular dilation, and chronic inflammatory cell infiltration.
Differential diagnosis: chronic eczematous dermatitis (unlike psoriasis, borders are indistinct and scale is less), seborrheic dermatitis (scalp- and face-centered, greasy yellow scale), secondary syphilis (palm and sole involvement, RPR/VDRL positive), mycosis fungoides (early cutaneous T-cell lymphoma), drug-induced psoriasiform reaction, and pustular psoriasis (impetigo herpetiformis). Psoriatic arthritis and reactive arthritis (Reiter syndrome) also require clinical distinction.
Treatment of severe psoriasis vulgaris aims at clearing skin lesions, preventing joint damage (when psoriatic arthritis accompanies), improving quality of life, and managing systemic comorbidities.
Narrowband ultraviolet B (NB-UVB, 311 nm) and PUVA are used for extensive moderate-to-severe psoriasis. Treatment three times weekly is standard, and 20–30 treatments are needed to achieve remission. Long-term PUVA is associated with increased risk of skin cancer (squamous cell carcinoma).
Methotrexate (MTX, 15–25 mg/week) is used as first-line systemic treatment for severe psoriasis and psoriatic arthritis. Hepatotoxicity (liver fibrosis) is the main adverse effect, and regular liver function monitoring is required. Cyclosporine (3–5 mg/kg/day) acts quickly but long-term use is limited by nephrotoxicity and hypertension. Acitretin is mainly used in psoriatic erythroderma and pustular psoriasis, and caution is needed in women of childbearing potential because of teratogenicity.
Anti-TNF agents: etanercept, adalimumab, infliximab, certolizumab pegol. PASI 75 achievement rate 50–70%. Anti-IL-17 agents: secukinumab (300 mg subcutaneous), ixekizumab, bimekizumab. Very high PASI 90/100 achievement rates (60–80%). Currently the most effective treatment option for severe psoriasis. Anti-IL-23p19 agents: guselkumab, risankizumab (150 mg subcutaneous every 4 weeks), tildrakizumab. PASI 90 achievement rate 60–75%, with high dosing convenience (12-week intervals). In Korea, guselkumab and risankizumab are covered by National Health Insurance (severe plaque psoriasis). Anti-IL-12/23 agents: ustekinumab (45/90 mg, 12-week intervals). The PASI 75 achievement rate (66–75%) is lower than anti-IL-17, but the dosing interval is long and the safety profile is excellent.
Deucravacitinib (a TYK2 inhibitor) received FDA approval for severe psoriasis in 2022. Given orally (6 mg once daily), it shows a higher PASI 75 achievement rate than anti-TNF (58.7% vs 35.9%).
Since the introduction of biologics, the prognosis of severe psoriasis vulgaris has improved markedly. With anti-IL-17 and anti-IL-23 agents, the PASI 90 (90% or greater skin improvement) achievement rate reaches 60–80%, and complete skin remission (PASI 100) is possible in some patients. However, psoriasis is a chronic relapsing disease, and relapse is common when treatment is stopped. The main factors worsening long-term prognosis in severe psoriasis are psoriatic arthritis (joint damage, disability), cardiovascular disease (myocardial infarction, stroke), metabolic syndrome, and depression/anxiety. Some studies indicate that the life expectancy of psoriasis patients is shortened by 3–5 years compared with the general population owing to increased cardiovascular mortality risk. However, aggressive treatment (biologics) and management of cardiovascular risk factors can narrow this gap.
Complete primary prevention of severe psoriasis vulgaris is not possible, but management of exacerbating factors and prevention of systemic complications are important. Management of exacerbating factors includes smoking cessation, moderation of alcohol intake, weight management (obesity affects psoriasis severity and response to biologics), stress management, minimizing skin trauma (preventing the Köbner phenomenon), and avoidance of causative drugs (beta-blockers, lithium, antimalarials). Prevention of systemic complications requires regular screening and active management of cardiovascular risk factors (hypertension, hyperlipidemia, diabetes), monitoring of musculoskeletal symptoms for early detection of psoriatic arthritis, and mental health support (depression/anxiety screening and linkage to treatment). During biologic treatment, vaccination to prevent infection (in particular, tuberculosis screening before starting biologics is mandatory) and annual influenza vaccination are recommended.